Many metal-on-metal hip arthroplasties (MoMHAs) with large femoral head diameters (36 mm or greater) have been implanted worldwide, either as hip resurfacing arthroplasty (HRA) or as total hip arthroplasty (THA) (Bozic et al. [@C11], NJR [@C105]). In recent years high short-term failure rates have been reported for most large-diameter MoMHA designs, which has led to an almost worldwide cessation of their use (Smith et al. [@C116], [@C117], AOANJRR [@C4], NJR [@C105]). Many MoMHA revisions have been performed for adverse reactions to metal debris (ARMD) (Langton et al. [@C67], [@C68]) and pseudotumor (a specific type of ARMD, defined as a cystic, solid, or mixed mass communicating with the joint) (Pandit et al. [@C106]). ARMD is the sequela of metal debris released from the bearing surface and/or other THA modular implant junctions due to wear and corrosion (Kwon et al. [@C57], Langton et al. [@C69], Matthies et al. [@C94], Langton et al. [@C71], Jacobs et al. [@C53]). This debris can result in destruction of the local bone and soft tissues, as well as large invasive pseudotumors, which often require revision surgery (Pandit et al. [@C106], Grammatopoulos et al. [@C37], Langton et al. [@C67]).

To identify ARMD early, regulatory authorities worldwide have published follow-up guidance for MoMHA patients (MHRA [@C98], FDA [@C31], Hannemann et al. [@C40]). Patients with ARMD may be asymptomatic which can make diagnosis difficult (Hart et al. [@C45], Fehring et al. [@C32]), therefore currently most MoMHA patients are regularly followed up for life. The main investigations used in surveillance are blood metal ions and cross-sectional imaging (ultrasound or metal artefact reduction sequence magnetic resonance imaging (MARS-MRI)) (MHRA [@C98], FDA [@C31], Hannemann et al. [@C40]). However, a recent review of MoMHA follow-up protocols issued by 5 worldwide authorities demonstrated that the guidance was extremely variable between authorities, not evidence-based and very costly (Matharu et al. [@C84]). Furthermore, there are still a number of questions that need to be addressed regarding the specific roles of each investigative modality during surveillance (Matharu et al. [@C84]).

This article is the first of 2 providing a clinical update on the investigation and management of MoMHA patients. The present article considers the various investigative modalities used during MoMHA surveillance, with specific focus on blood metal ion sampling and imaging. The second article considers the threshold for performing revision, and the outcomes following ARMD revision surgery (Acta Orthop 2018; in press).

Blood metal ions {#s0002}
================

Rationale, methods, and interpretation {#s0003}
--------------------------------------

Blood metal ion concentrations are a surrogate marker of in-vivo wear in MoMHAs, and therefore have been used to investigate patients (De Smet et al. [@C24]). Cobalt and chromium ions are measured, which constitute the primary elements of the MoM alloy. Wear (normal and excessive) and corrosion of MoMHAs causes release of both insoluble metal particles (found in the synovial fluid and periprosthetic tissues) and soluble metal ions (entering the bloodstream thus allowing measurement) (McMinn [@C96]).

Whole blood or serum samples are used for measuring these metal ion concentrations. Samples should be collected, stored, transported, and processed according to laboratory guidance. Analysis must be performed at an accredited laboratory with expertise in trace metal element analysis, with excellent accuracy of measurement and reproducibility reported (Harrington and Taylor [@C41]). Samples are analyzed using dynamic reaction cell or collision cell inductively coupled plasma mass spectrometry.

Serial samples should be sent to the same laboratory given that clinically significant variations can occur in blood samples from the same patients analyzed at different laboratories (Rahme et al. [@C107]). To prevent incorrect interpretation of serial results the same blood fraction must be used. Whole blood is preferred given that serum requires further preparation (centrifuging), which increases the risk of contamination (Daniel et al. [@C17]). Serum cobalt and chromium are up to 1.4 times greater than their respective values in whole blood, with stronger correlation of cobalt in serum and whole blood compared with that of chromium (Vendittoli et al. [@C127], Engh et al. [@C29]).

Advantages of blood metal ion sampling include being relatively inexpensive (£30 per test) (Lloyd et al. [@C76]) and simple to conduct. Disadvantages relate to potential patient (renal function, diet/medication/supplements containing trace metals, occupational exposure, other metal eluting implants) and laboratory (contamination, inter-laboratory, and intra-laboratory measurement variability) factors that can influence test interpretation (Daniel et al. [@C19], FDA [@C31], Rahme et al. [@C107]). Therefore, management decisions should never be solely based on 1 blood test.

Blood metal ions in healthy controls and well-functioning hips {#s0004}
--------------------------------------------------------------

97% of healthy subjects have both blood cobalt and chromium concentrations of 2 µg/L or less, with little variation observed between individuals (Sidaginamale et al. [@C113]). In well-functioning MoMHAs, metal ions can enter the bloodstream by day 5 following implantation (Daniel et al. [@C17]). Blood metal ion concentrations then increase significantly over the first year during the bearing running-in phase (Heisel et al. [@C50]). Concentrations then either stabilize or slowly decrease from 1 year postoperatively during medium-term follow-up (Daniel et al. [@C17], [@C18], Amstutz et al. [@C2]). However, some authors have also observed significantly decreased blood metal ion concentrations by 10 years (Bernstein et al. [@C9], Van Der Straeten et al. [@C122], [@C123]).

Factors influencing blood metal ion concentrations {#s0005}
--------------------------------------------------

High blood metal ion concentrations in MoMHA patients have been associated with poorly functioning implants (Hart et al. [@C43], Van Der Straeten et al. [@C122], Hart et al. [@C46]), including those specifically revised for ARMD (Langton et al. [@C67], Sidaginamale et al. [@C113], Lainiala et al. [@C63], Langton et al. [@C73]). Predictors of raised blood metal ion concentrations can be divided into patient (female sex, young age, time since implantation), implant (design, small femoral HRA components, large femoral MoM THA components, bilateral MoMHAs), and surgical factors (acetabular component malposition, reduced contact patch to rim distance) (De Haan et al. [@C23], Langton et al. [@C66], Grammatopoulos et al. [@C38], Bernstein et al. [@C8], Hart et al. [@C44], Langton et al. [@C70], Lavigne et al. [@C74], Chang et al. [@C14], Van Der Straeten et al. [@C122], Emmanuel et al. [@C28], Matthies et al. [@C95], Matharu et al. [@C82], [@C83], Lainiala et al. [@C65]).

A recent large study involving 1,748 patients with different MoMHA implant designs observed that MoM THAs had significantly higher blood metal ion concentrations compared with HRA patients (Lainiala et al. [@C65]). This confirms the findings from 2 randomized controlled trials of MoM THAs and HRAs with identical bearing surfaces (Garbuz et al. [@C33], Beaule et al. [@C5]), with the higher metal ion concentrations in MoM THAs likely to be related to the additional wear and corrosion occurring at the modular implant junction(s).

Blood metal ion thresholds for clinical use {#s0006}
-------------------------------------------

There is presently no international consensus on the acceptable metal ion threshold(s) of concern in MoMHA patients. Since 2010, blood cobalt and/or chromium concentrations above 7 µg/L have been considered a cause for concern by some authorities (MHRA [@C97], Canada [@C13], MHRA [@C98], [@C99]). Initial reports suggested that this arbitrarily selected threshold had good specificity (89%) but poor sensitivity (52%) for detecting unilateral failed MoMHAs, with the optimal threshold identified as a cobalt or chromium of 5.0 µg/L (86% specificity and 63% sensitivity) (Hart et al. [@C43]). Others have reported similar findings (Malek et al. [@C80]). A subsequent study involving 597 unilateral MoMHAs identified 7 µg/L as having nearly optimal misclassification rates, although the authors suggested blood metal ions should not be used alone for screening for failed implants (Hart et al. [@C46]).

Thresholds for poorly functioning HRAs have been proposed by Van Der Straeten et al. ([@C122]) (cobalt 4.0 µg/L and chromium 4.6 µg/L for unilateral HRA) and others (cobalt 4.5 µg/L) (Sidaginamale et al. [@C113]) with all cut-offs having higher specificity than sensitivity. Similar findings were observed in poorly functioning bilateral HRAs (Van Der Straeten et al. [@C122]). Blood metal ion concentrations above 20 µg/L have been associated with osteolysis at ARMD revision, therefore it was recommended that revision should be considered in patients above this threshold (Langton et al. [@C72]). More recently a US consensus statement proposed risk-stratifying MoMHA patients to assist management with blood cobalt and chromium concentrations arbitrarily grouped into low risk (\< 3 µg/L), moderate risk (3--10 µg/L), and high risk (\> 10 µg/L) (Kwon et al. [@C59]).

2 large cohort studies involving 783 MoMHA patients recently devised implant-specific blood metal ion thresholds for unilateral Birmingham Hip Resurfacings (BHRs, Smith & Nephew, Warwick, UK: cobalt 2.15 µg/L), bilateral BHRs (maximum cobalt or chromium 5.5 µg/L), and unilateral Corail-Pinnacle THAs (DePuy, Leeds, UK: cobalt 3.57 µg/L) (Matharu et al. [@C85], [@C86]). Patients with ion concentrations below the respective newly devised thresholds were at a low risk of having ARMD. However, these new thresholds were not effective for identifying patients who had ARMD. Currently proposed fixed regulatory authority thresholds from the UK MHRA and US surgeons missed more patients with ARMD compared with the newly devised thresholds (MHRA [@C98], Kwon et al. [@C59]). The findings from these 2 studies were successfully validated in 710 patients from 3 different European centers (Matharu et al. [@C91]). It was therefore recommended that the newly devised implant-specific blood metal ion thresholds should be used in preference to fixed regulatory authority thresholds when managing MoMHA patients.

Repeat blood metal ion sampling {#s0007}
-------------------------------

After repeating blood metal ions within 1 year in 254 unilateral Articular Surface Replacement (ASR, DePuy) patients, 1 study observed that most HRAs had concentrations below published thresholds (Van Der Straeten et al. [@C122]) on both tests, whilst one-third of MoM THAs with normal initial cobalt concentrations experienced significant increases on repeat testing (Reito et al. [@C109]). Similar observations were reported in bilateral ASR patients undergoing repeat blood testing (Reito et al. [@C110]). Another study repeating blood metal ions during the short term in 205 patients with HRAs observed that cobalt concentrations did not significantly change with time since implantation (Langton et al. [@C72]).

Hip imaging {#s0008}
===========

Radiographs {#s0009}
-----------

Conventional radiographs provide important information on component position, bone quality, and implant fixation, therefore they can identify signs suggestive of MoMHA failure early (Chen et al. [@C15]). However radiographs cannot directly diagnose ARMD or pseudotumors, given that these are predominantly soft-tissue lesions (Johnston et al. [@C54], Toms et al. [@C121]), but they can identify associated abnormalities including component loosening, osteolysis, femoral neck narrowing, component malposition, fracture, subluxation/dislocation, and in HRAs femoral neck erosion due to impingement (Grammatopoulos et al. [@C38], [@C39], Chen et al. [@C15], De Smet et al. [@C25], Langton et al. [@C69], Kwon et al. [@C59], Matharu et al. [@C81]). Furthermore, radiographs can identify other causes of hip pain, such as heterotopic ossification (HO) (Chen et al. [@C15]).

When assessing radiographs, it is important to compare serial images, including the immediate post-primary radiograph, for subtle signs of MoMHA failure. Medial calcar erosion represents a radiographic sign suggestive of ARMD in MoM THAs (Madanat et al. [@C79]). A recent case-control study involving 384 HRAs demonstrated that radiographic factors predictive of hips with evidence of a pseudotumor included acetabular component malposition (high inclination, and anteversion below 5 degrees), acetabular osteolysis, femoral osteolysis, acetabular loosening, and the absence of HO (Matharu et al. [@C92]). However, it was recommended that radiographs should not be considered a substitute for performing blood metal ions and cross-sectional imaging, given that 20% of HRAs revised for pseudotumors had normal radiographs (Matharu et al. [@C92]). It remains unclear whether femoral neck narrowing represents a normal physiological process following HRA or a clinically significant finding given that neck narrowing has been reported in both well-functioning patients (Hing et al. [@C51], Coulter et al. [@C16], Daniel et al. [@C20]) and ARMD revisions (Chen et al. [@C15], Matharu et al. [@C81]).

Advantages of conventional radiographs when assessing MoMHAs include their wide availability, low cost, and ease of interpretation, with the main disadvantage being pelvic radiation exposure.

Ultrasound {#s0010}
----------

Ultrasound has frequently been used as the initial imaging modality for investigating MoMHA patients (Fang et al. [@C30], Douis et al. [@C26], Nishii et al. [@C103]). Compared with MARS-MRI, the main advantages of ultrasound include being cheaper (ultrasound £49 vs. MARS-MRI £216) (Lloyd et al. [@C76]), faster to perform, not being affected by prosthetic artefacts, and being more accessible with fewer patient contraindications (can be used in patients with pacemakers or those with claustrophobia) (Siddiqui et al. [@C115]). Ultrasound also permits dynamic imaging, hip aspirations, and biopsies (Kwon et al. [@C58], Siddiqui et al. [@C115]). The main disadvantages of ultrasound include the technique being operator dependent, and difficulties when assessing deeper structures or examining larger patients (Kwon et al. [@C59], Siddiqui et al. [@C115]).

Ultrasound can identify numerous abnormalities around MoMHAs (Nishii et al. [@C103]), including pseudotumors of variable sizes, which are often cystic or solid and located anterior or posterolateral to MoMHAs (Figure) (Fang et al. [@C30], Kwon et al. [@C58], Williams et al. [@C129], Nishii et al. [@C103]). A recent study of 82 MoMHAs undergoing revision concluded that ultrasound was effective for intraoperative detection of pseudotumors (Lainiala et al. [@C64]). Ultrasound has also been useful for detecting other ARMD pathology including joint effusions, iliopsoas and trochanteric bursal collections, capsular and bursal thickening, and synovitis (Douis et al. [@C26], Nishii et al. [@C103]). Other abnormalities that ultrasound can identify, which may not always be related to ARMD, include muscle atrophy and tendon avulsions (Sofka et al. [@C118], Garcia et al. [@C35]).

3 systems for classifying ARMD abnormalities on ultrasound have been proposed (Nishii et al. [@C103], Siddiqui et al. [@C114], Matharu et al. [@C87]). It must be acknowledged that the prevalence of ARMD in MoMHAs on both ultrasound and MARS-MRI has been much higher (up to 61%) (Kwon et al. [@C58], Williams et al. [@C129], Hart et al. [@C45], Fehring et al. [@C32]) than that confirmed at revision surgery (Langton et al. [@C73], Matharu et al. [@C88], [@C93]). As ARMD on imaging has now frequently been observed around well-functioning conventional THAs (Bisseling et al. [@C10], van der Veen et al. [@C124], Das et al. [@C21]), it is possible that current cross-sectional imaging classifications have over-diagnosed imaging ARMD in MoMHA patients (Anderson et al. [@C3], Hart et al. [@C45], Hauptfleisch et al. [@C48], Nishii et al. [@C103], Siddiqui et al. [@C114], Matharu et al. [@C87]).

Ultrasound has a role in identifying both the development and progression of ARMD. Repeat ultrasound in a small MoMHA cohort with asymptomatic ARMD on initial imaging demonstrated that most lesions increased in size in the short term with occasional remission of small masses (Almousa et al. [@C1]). By contrast, a recent study repeated ultrasounds in 10 HRAs with asymptomatic pseudotumors between 4.0 and 6.5 years later, with no changes occurring in pseudotumor volume or patient reported outcomes (Matharu et al. [@C90]). This may suggest that some asymptomatic ARMD lesions can be safely left and only monitored with interval scanning.

A recent prospective longitudinal study of 152 asymptomatic HRAs demonstrated that 10% developed new pseudotumors on ultrasound within 5 years of initial assessment (Low et al. [@C78]). No asymptomatic patients with both a normal initial ultrasound and low blood metal ions (\< 2 µg/L) developed new pseudotumors within 5 years of initial assessment (33% of hips studied). It was therefore concluded that these particular patients do not need regular follow-up. As large cohort studies have reported that 84% of all comprehensively investigated HRA patients were asymptomatic with well-functioning devices (Hart et al. [@C46]), it is estimated that 28% of all hip resurfacing patients would be asymptomatic with normal cross-sectional imaging and low blood metal ions. These findings have important clinical and financial implications, given that several protocols recommend intensive surveillance for asymptomatic HRA patients (Therapeutic Goods Administration [@C119], Hannemann et al. [@C40], MHRA [@C99]). By contrast asymptomatic HRA patients with normal initial ultrasounds alone but ions of 2 µg/L or above, and those asymptomatic HRA patients with low blood metal ions but abnormal imaging both still had a small, but potentially clinically significant, risk of developing new pseudotumors within 5 years of initial assessment (Low et al. [@C78]). Therefore it was recommended that this patient subgroup required some form of surveillance within 5 years of initial assessment.

MARS-MRI {#s0011}
--------

Most centers use MARS-MRI as the initial cross-sectional imaging modality for investigating MoMHAs, which is likely to be increasingly used as techniques become refined (Kwon et al. [@C59]). MARS-MRI is not operator dependent, it provides excellent visualization of soft-tissue structures including deeper tissues, and images can be assessed retrospectively, which is helpful when obtaining further opinions or planning revision (Liddle et al. [@C75], Siddiqui et al. [@C115]). Comparison can be made with the contralateral hip, and it is also easier to compare serial MARS-MRI images rather than serial ultrasounds (Siddiqui et al. [@C115]). The main disadvantages of MARS-MRI include the high cost (£216), periprosthetic metal artefact despite suppression techniques, longer examination times, reduced availability, and being contraindicated in patients with pacemakers (Siddiqui et al. [@C115]).

Using an optimized MARS-MRI protocol allows detection of numerous abnormalities around MoMHAs. Pseudotumors are frequently of variable sizes, located anterior or posterolateral to MoMHAs, with a cystic, solid, or mixed consistency (Wynn-Jones et al. [@C130], Hart et al. [@C45], Hauptfleisch et al. [@C48], Fehring et al. [@C32]). 3 main MARS-MRI pseudotumor classification systems have been proposed (Anderson et al. [@C3], Hart et al. [@C45], Hauptfleisch et al. [@C48]). Comparison of these systems suggested the Anderson et al. classification was most reliable (van der Weegen et al. [@C126]). The Modified Oxford Classification has been proposed more recently (Briant-Evans et al. [@C12]), which classifies MARS-MRI scans initially into 4 groups (normal, trochanteric fluid, effusion, ARMD), with the ARMD group subsequently classified according to others (Hauptfleisch et al. [@C48]). However small periprosthetic effusions may still be missed because of prosthetic artefacts (Siddiqui et al. [@C115]).

When pseudotumors have been detected, MARS-MRI can provide detailed information regarding any soft-tissue or muscle invasion and destruction as well as neurovascular involvement, which assists when planning revision (Liddle et al. [@C75]). Furthermore, studies by Liddle et al. ([@C75]) (85% sensitivity and 59% specificity) and Lainiala et al. ([@C62]) (71% sensitivity and 87% specificity) have demonstrated that MARS-MRI is effective for diagnosing intraoperative pseudotumors. The latter study also reported that these results varied with MARS-MRI timing, with scans performed more than 1 year before revision surgery having lower sensitivity (29%) for detecting intraoperative pseudotumors compared with scans performed within 1 year before revision (77--88% sensitivity) (Lainiala et al. [@C62]).

Other ARMD abnormalities also detected on MARS-MRI include muscle atrophy, tendon avulsions, and osteolysis (Hayter et al. [@C49], Siddiqui et al. [@C115], Berber et al. [@C7], Matharu et al. [@C87]). Hip abductor atrophy has frequently been reported in MoMHAs and can progress over 1 year, with some suggesting atrophy may be a precursor to irreversible muscle destruction (Berber et al. [@C7]).

Like ultrasound, MARS-MRI can identify both the development and progression of ARMD associated with MoMHAs. Most studies repeating MARS-MRI in MoMHA patients with normal initial scans have observed that few changes occur within 2 years of repeat imaging (van der Weegen et al. [@C125], Reito et al. [@C108]), with any development of ARMD from normal scans occurring over several years (Ebreo et al. [@C27]). By contrast, a study of 155 MoM THAs undergoing repeat MARS-MRI within a mean time of 15 months after the initial imaging observed that the risk of disease progression was high in patients with initially normal scans (30%), and in those with isolated trochanteric fluid (47%) and effusions (58%) on initial MARS-MRI (Briant-Evans et al. [@C12]). Disease progression on imaging was associated with high blood cobalt concentrations, or an irregular pseudocapsule lining at initial MARS-MRI (Briant-Evans et al. [@C12]).

Of the 4 studies repeating MARS-MRI in MoMHA patients with asymptomatic pseudotumors, 3 reported either little change or partial regression with serial imaging (van der Weegen et al. [@C125], Kwon et al. [@C61], Goldstein et al. [@C36]). The other, a small study of 24 hips, observed that pseudotumors frequently changed in size when MARS-MRI was repeated, with larger lesions most likely to increase (Hasegawa et al. [@C47]).

Ultrasound vs. MARS-MRI {#s0012}
-----------------------

A number of studies have compared ultrasound and MARS-MRI for detecting ARMD (Table) (Garbuz et al. [@C34], Nishii et al. [@C104], Siddiqui et al. [@C115], Muraoka et al. [@C101], Kwon et al. [@C60], Matharu et al. [@C89]). The benchmark for diagnostic accuracy in such studies should be correlation with the findings at revision; however, most did not use intraoperative findings as the reference standard. Studies have largely demonstrated that ultrasound was effective for identifying pseudotumors on MARS-MRI, and therefore recommended ultrasound for initial screening, with MARS-MRI reserved if ultrasound abnormalities required further assessment (Garbuz et al. [@C34], Nishii et al. [@C104], Muraoka et al. [@C101], Kwon et al. [@C60]). 1 study concluded that a negative ultrasound excluded pseudotumor in asymptomatic patients; ultrasound was 100% sensitive (Garbuz et al. [@C34]). Furthermore another study repeated both the ultrasound and MARS-MRI in 42 MoMHAs after a mean time of 14 months; when ultrasound was repeated it was accurately able to detect changes in ARMD lesion size and grade, therefore suggesting ultrasound is effective in the longitudinal assessment of MoMHA patients (Kwon et al. [@C60]). By contrast, the authors of the smallest study reported that ultrasound was inferior to MARS-MRI for detecting pseudotumors and muscle atrophy, but ultrasound was superior to MARS-MRI for diagnosing effusions and tendon pathology (Siddiqui et al. [@C115]).

A recent retrospective diagnostic accuracy study of 40 HRAs subsequently requiring revision surgery for any reason compared the imaging findings prior to revision with the intraoperative findings (Matharu et al. [@C89]). It was concluded that ultrasound and MARS-MRI both have a role when assessing HRA patients requiring revision, which parallels other studies where either ultrasound or MARS-MRI alone was performed (Liddle et al. [@C75], Lainiala et al. [@C62], [@C64]). However, combined imaging using ultrasound and MARS-MRI was most effective for both identifying and excluding intraoperative pseudotumors (Table 1). These observations suggest that combined imaging may be useful in more complex clinical cases, such as symptomatic patients with either a normal initial ultrasound or MARS-MRI.

Computed tomography {#s0013}
-------------------

Computed tomography (CT) scanning provides useful information regarding MoMHA component positioning and fixation, and can also detect osteolysis or fractures, which may be radiographically occult (Hart et al. [@C42], Roth et al. [@C112], Liddle et al. [@C75]). However, CT appears unsuitable for routine MoMHA imaging with a sensitivity of 44% for diagnosing pseudotumors compared with MARS-MRI, although CT was superior for detecting osteolysis (Robinson et al. [@C111]).

Given the advantages of both ultrasound and MARS-MRI, CT should not be recommended as a first-line MoMHA imaging modality (FDA [@C31], Hannemann et al. [@C40]). Furthermore, CT is associated with pelvic radiation, image artefact from prostheses, and high costs.

Other investigations {#s0014}
====================

Infection and ARMD can have similar presentations, therefore a comprehensive assessment is required. This includes blood tests for the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Infected MoMHA revision patients have significantly higher ESR and CRP values compared with non-infected revision cases (which included ARMD failures) (Yi et al. [@C131]). However, the ESR and CRP may also be raised in aseptic ARMD patients (Pandit et al. [@C106], Mikhael et al. [@C100]), and where ARMD and infection coexist (Watters et al. [@C128], Judd and Noiseux [@C55], Matharu et al. [@C81]).

Hip aspirations can help assess infection (synovial fluid culture, sensitivity, white blood cell count, and cell differential, i.e. percentage of polymorphonuclear cells) (Lombardi et al. [@C77], Yi et al. [@C131]) and ARMD (synovial cobalt and chromium concentrations) (De Smet et al. [@C24], Langton et al. [@C67], Davda et al. [@C22], Kwon et al. [@C58]). Synovial metal ion concentrations can assist in cases where blood metal ions and cross-sectional imaging have been equivocal despite clinical concerns, and may be informative when patients have problematic bilateral MoMHAs. In a recent study leukocyte esterase strip testing of synovial fluid samples was reliable at ruling out infection in MoMHAs revised for ARMD (Tischler et al. [@C120]).

Other useful investigations for unexplained symptoms include single-photon emission CT (Berber et al. [@C6]), diagnostic hip injections, and investigating other causes (such as spinal or non-orthopedic pathology).

Symptoms and patient-reported outcome measures {#s0015}
==============================================

When interpreting the results of any investigations performed in MoMHA patients, pain and functional limitations should be assessed. Symptoms and signs looked for are pain (groin, buttock, lateral hip, or thigh), swellings or masses, mechanical symptoms (clicking, clunking, grinding, squeaking, catching, or instability), or a limp when walking. Patient-reported outcome measures such as the Oxford Hip Score (OHS) and Harris Hip Score (HHS) are reliable and responsive instruments; however, regulatory authorities do not currently provide guidance on meaningful thresholds for stratifying MoMHA patients (Matharu et al. [@C84]).

An OHS less than 34, or an HHS less than 80 (Kalairajah et al. [@C56], Murray et al. [@C102]) could be considered suboptimal patient-reported outcome measures following MoMHA that warrant further investigation. Indeed, a recent large cohort study which developed a clinical scoring system for assessing the risk of revision in 1,434 MoMHAs identified the HHS and blood metal ion levels as the most important predictors of revision. The HHS was subsequently categorized into low risk (80--100), moderate risk (70--79), and high risk (\< 70) groups (Hussey et al. [@C52]). Patient-reported outcome measures therefore seem important for risk stratifying MoMHA patients who otherwise may not appear to be symptomatic for surveillance and/or further investigation.

Conclusions {#s0016}
===========

Many studies have assessed various investigative modalities used in MoMHA surveillance. No single investigation can universally be used during surveillance based on our literature update. We recommend that all MoMHA patients undergo a complete clinical assessment as a baseline. This assessment should include blood metal ion concentrations, cross-sectional imaging, and pelvic radiographs as well as completion of validated patient-reported outcome measures. The choice of cross-sectional imaging modality (ultrasound or MARS-MRI) used will depend on the availability of ultrasound expertise at each institution as well as any financial constraints. Subsequent patient management will depend on a combination of the results of this clinical assessment, hip symptoms, and the patient's risk of ARMD (Grammatopoulos et al. [@C38], Matharu et al. [@C88]).

Recent studies have provided information about (1) interpreting blood metal ions (effective at identifying patients at low risk of ARMD), (2) the roles of cross-sectional imaging (reserve combined ultrasound and MARS-MRI for complex cases), and (3) providing evidence-based parameters (blood metal ions \<2 µg/L and normal cross-sectional imaging) to safely exclude many asymptomatic patients from regular surveillance. The latter issue is particularly important in asymptomatic HRA patients and could result in considerable financial savings, given that the current recommendations from regulatory authorities for this subgroup vary ranging from local protocol (MHRA [@C98]) to annual radiographs and blood metal ions (Hannemann et al. [@C40]). Therefore, the findings from recent studies will be useful when designing future surveillance protocols for MoMHA patients. However, the natural history of ARMD remains incompletely understood. Further longitudinal studies are thus needed to identify specifically which clinical, laboratory, and imaging findings predict patients with aggressive ARMD requiring revision surgery.
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###### 

Summary of studies comparing ultrasound and MARS-MRI for detecting adverse reactions to metal debris and pseudotumors

                                                                                                             Positive   Negative
  ---------------------------------------------------------------------------------------------- ----- ----- ---------- ----------
  Garbuz et al. [@C34] (40 hips)                                                                                        
   Ultrasound vs. MARS-MRI[^a^](#TF2){ref-type="table-fn"}                                       100   96    92         100
   MARS-MRI vs. ultrasound[^a^](#TF2){ref-type="table-fn"}                                       92    100   100        96
  Siddiqui et al. [@C115] (19 hips)                                                                                     
   Ultrasound vs. MARS-MR[^a^](#TF2){ref-type="table-fn"}                                        69    83    90         56
  Nishii et al. [@C104] (64 hips)                                                                                       
   Ultrasound vs. MARS-MRI[^a^](#TF2){ref-type="table-fn"}                                       74    92    NS         NS
  Muraoka et al. [@C101] (83 hips)                                                                                      
   Ultrasound vs. MARS-MRI[^a^](#TF2){ref-type="table-fn"}                                       72    88    65         91
  Kwon et al. [@C60] (42 hips)                                                                                          
   Initial: Ultrasound vs. MARS-MRI[^a^](#TF2){ref-type="table-fn"}                              81    92    86         88
   Repeat: Ultrasound vs. MARS-MRI[^a^](#TF2){ref-type="table-fn"}                               86    88    75         94
  Matharu et al. [@C89] (40 hips)                                                                                       
   Ultrasound vs. intraoperative[^a^](#TF2){ref-type="table-fn"}                                 91    43    88         50
   MARS-MRI vs. intraoperative[^a^](#TF2){ref-type="table-fn"}                                   94    57    91         67
   Combined imaging (ultrasound & MARS-MRI) vs. intraoperative[^a^](#TF2){ref-type="table-fn"}   100   57    92         100

NS = not stated.

Gold reference standard for diagnostic test characteristics

![Pseudotumor in association with a metal-on-metal hip resurfacing arthroplasty identified on ultrasound examination. Anterior view of the hip demonstrating an enlarged mixed pseudotumor lying in the psoas bursa region. The pseudotumor lies in close proximity to the femoral vessels (marked) and has a smaller medial (M) and a larger lateral (L) component.](iort-89-29.F01){#F0001}
